Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of patients were alive at one year versus 53% with IMFINZI alone, and progression-free survival more than tripled. The findings suggest IMDELLTRA could significantly improve treatment outcomes in a disease with historically poor survival rates. Amgen plans to seek regulatory approvals worldwide based on these results.
Amgen (AMGN) trades at USD 439.26, down 1.79% as of Oct 24, 2026 21:41 WIB on Pluang. AstraZeneca (AZN) is priced at USD 171.49, down 0.63% at the same time. AMGN's market cap is $237.48B, while AZN's is $266.57B, showing strong market presence despite recent sell-heavy order activity on Pluang.
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen will hold a webcast on October 24, 2026, during the European Society of Medical Oncology Congress (ESMO) to discuss its oncology portfolio and present selected data. The event will feature senior executives including Murdo Gordon and Jean-Charl...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Amgen and AstraZeneca announced positive Phase 3 CROSSING trial results for TEZSPIRE (tezepelumab-ekko), demonstrating significant and lasting improvements in patients with eosinophilic esophagitis (EoE). The drug achieved histologic remission in abo...
